Alkermes (ALKS) to Release Earnings on Tuesday

Alkermes (NASDAQ:ALKS) is projected to release its Q2 2026 results before the market opens on Tuesday, July 28th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $457.4070 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, July 28, 2026 at 8:00 AM ET.

Alkermes Stock Performance

Alkermes stock opened at $52.89 on Monday. The firm has a market capitalization of $8.82 billion, a PE ratio of 58.77 and a beta of 0.34. Alkermes has a one year low of $25.17 and a one year high of $55.67. The stock’s 50 day moving average price is $46.92 and its 200 day moving average price is $37.50. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.70 and a current ratio of 2.27.

Insider Buying and Selling

In related news, EVP Craig C. Hopkinson sold 9,000 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $51.51, for a total value of $463,590.00. Following the sale, the executive vice president directly owned 73,389 shares of the company’s stock, valued at $3,780,267.39. This represents a 10.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher I. Wright sold 2,000 shares of the stock in a transaction on Friday, June 12th. The shares were sold at an average price of $45.10, for a total transaction of $90,200.00. Following the transaction, the director owned 25,680 shares in the company, valued at $1,158,168. This trade represents a 7.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 35,102 shares of company stock worth $1,494,410. Insiders own 4.59% of the company’s stock.

Hedge Funds Weigh In On Alkermes

A number of hedge funds have recently bought and sold shares of the company. Royal Bank of Canada raised its stake in Alkermes by 117.2% during the first quarter. Royal Bank of Canada now owns 275,526 shares of the company’s stock valued at $9,098,000 after buying an additional 148,696 shares in the last quarter. Ashton Thomas Private Wealth LLC acquired a new position in shares of Alkermes in the 1st quarter worth approximately $213,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Alkermes by 4.3% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 482,332 shares of the company’s stock worth $15,927,000 after acquiring an additional 20,091 shares in the last quarter. Cetera Investment Advisers increased its holdings in shares of Alkermes by 32.3% in the 2nd quarter. Cetera Investment Advisers now owns 13,907 shares of the company’s stock valued at $398,000 after acquiring an additional 3,394 shares during the last quarter. Finally, Quantbot Technologies LP increased its holdings in shares of Alkermes by 539.4% in the 2nd quarter. Quantbot Technologies LP now owns 6,976 shares of the company’s stock valued at $200,000 after acquiring an additional 5,885 shares during the last quarter. 95.21% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Zacks Research raised shares of Alkermes from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Royal Bank Of Canada raised their price target on shares of Alkermes from $45.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, June 9th. Robert W. Baird lifted their price target on shares of Alkermes from $45.00 to $48.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 13th. Bank of America reiterated an “underperform” rating on shares of Alkermes in a report on Monday, June 29th. Finally, Needham & Company LLC lifted their target price on Alkermes from $61.00 to $62.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Alkermes currently has a consensus rating of “Moderate Buy” and an average price target of $52.50.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.